Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

Mads Barloese; Anja Petersen; Philipp Stude; Tim Jürgens; Rigmor Højland Jensen; Arne May

doi:10.1186/s10194-017-0828-9

Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

Mads Barloese, Anja Petersen, Philipp Stude, Tim Jürgens, Rigmor Højland Jensen, Arne May

Institut for Klinisk Medicin

29 Citationer (Scopus)

32 Downloads (Pure)

Abstract

BACKGROUND: Cluster headache (CH) is a disabling primary headache disorder characterized by severe periorbital pain. A subset of patients does not respond to established pharmacological therapy. This study examines outcomes of a cohort of mainly chronic CH patients treated with sphenopalatine ganglion (SPG) stimulation.

METHODS: Patients were followed in an open-label prospective study for 12 months. Ninety-seven CH patients (88 chronic, 9 episodic) underwent trans-oral insertion of a microstimulator targeting the SPG. Patients recorded stimulation effect prospectively for individual attacks. Frequency, use of preventive and acute medications, headache impact (HIT-6) and quality of life measures (SF-36v2) were monitored at clinic visits. Per protocol, frequency responders experienced ≥ 50% reduction in attack frequency and acute responders treated ≥ 50% of attacks. HIT-6 responders experienced an improvement ≥ 2.3 units and SF-36 responders ≥ 4 units vs. baseline.

RESULTS: Eighty-five patients (78 chronic, 7 episodic) remained implanted and were evaluated for effectiveness at 12 months. In total, 68% of all patients were responders, 55% of chronic patients were frequency responders and 32% of all patients were acute responders. 67% of patients using acute treatments were able to reduce the use of these by 52% and 74% of chronic patients were able to stop, reduce or remain off all preventive medications. 59% of all patients were HIT-6 responders, 67% were SF-36 responders.

CONCLUSIONS: This open-label registry corroborates that SPG stimulation is an effective therapy for CH patients providing therapeutic benefits and improvements in use of medication as well as headache impact and quality of life.

Originalsprog	Engelsk
Artikelnummer	6
Tidsskrift	The Journal of Headache and Pain
Vol/bind	19
Antal sider	8
ISSN	1129-2369
DOI	https://doi.org/10.1186/s10194-017-0828-9
Status	Udgivet - 1 dec. 2018

Adgang til dokumentet

10.1186/s10194-017-0828-9Licens: CC BY

s10194-017-0828-9Forlagets udgivne version, 786 KBLicens: CC BY

Citationsformater

@article{830d5ea88e0649a5b557fdac9ead22fc,

title = "Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry",

abstract = "BACKGROUND: Cluster headache (CH) is a disabling primary headache disorder characterized by severe periorbital pain. A subset of patients does not respond to established pharmacological therapy. This study examines outcomes of a cohort of mainly chronic CH patients treated with sphenopalatine ganglion (SPG) stimulation.METHODS: Patients were followed in an open-label prospective study for 12 months. Ninety-seven CH patients (88 chronic, 9 episodic) underwent trans-oral insertion of a microstimulator targeting the SPG. Patients recorded stimulation effect prospectively for individual attacks. Frequency, use of preventive and acute medications, headache impact (HIT-6) and quality of life measures (SF-36v2) were monitored at clinic visits. Per protocol, frequency responders experienced ≥ 50% reduction in attack frequency and acute responders treated ≥ 50% of attacks. HIT-6 responders experienced an improvement ≥ 2.3 units and SF-36 responders ≥ 4 units vs. baseline.RESULTS: Eighty-five patients (78 chronic, 7 episodic) remained implanted and were evaluated for effectiveness at 12 months. In total, 68% of all patients were responders, 55% of chronic patients were frequency responders and 32% of all patients were acute responders. 67% of patients using acute treatments were able to reduce the use of these by 52% and 74% of chronic patients were able to stop, reduce or remain off all preventive medications. 59% of all patients were HIT-6 responders, 67% were SF-36 responders.CONCLUSIONS: This open-label registry corroborates that SPG stimulation is an effective therapy for CH patients providing therapeutic benefits and improvements in use of medication as well as headache impact and quality of life.",

keywords = "Adult, Aged, Cluster Headache/therapy, Electric Stimulation Therapy/instrumentation, Europe, Female, Ganglia, Parasympathetic, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Prospective Studies, Registries, Young Adult",

author = "Mads Barloese and Anja Petersen and Philipp Stude and Tim J{\"u}rgens and Jensen, {Rigmor H{\o}jland} and Arne May",

year = "2018",

month = dec,

day = "1",

doi = "10.1186/s10194-017-0828-9",

language = "English",

volume = "19",

journal = "The Journal of Headache and Pain",

issn = "1129-2369",

publisher = "Springer",

}

TY - JOUR

T1 - Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

AU - Barloese, Mads

AU - Petersen, Anja

AU - Stude, Philipp

AU - Jürgens, Tim

AU - Jensen, Rigmor Højland

AU - May, Arne

PY - 2018/12/1

Y1 - 2018/12/1

N2 - BACKGROUND: Cluster headache (CH) is a disabling primary headache disorder characterized by severe periorbital pain. A subset of patients does not respond to established pharmacological therapy. This study examines outcomes of a cohort of mainly chronic CH patients treated with sphenopalatine ganglion (SPG) stimulation.METHODS: Patients were followed in an open-label prospective study for 12 months. Ninety-seven CH patients (88 chronic, 9 episodic) underwent trans-oral insertion of a microstimulator targeting the SPG. Patients recorded stimulation effect prospectively for individual attacks. Frequency, use of preventive and acute medications, headache impact (HIT-6) and quality of life measures (SF-36v2) were monitored at clinic visits. Per protocol, frequency responders experienced ≥ 50% reduction in attack frequency and acute responders treated ≥ 50% of attacks. HIT-6 responders experienced an improvement ≥ 2.3 units and SF-36 responders ≥ 4 units vs. baseline.RESULTS: Eighty-five patients (78 chronic, 7 episodic) remained implanted and were evaluated for effectiveness at 12 months. In total, 68% of all patients were responders, 55% of chronic patients were frequency responders and 32% of all patients were acute responders. 67% of patients using acute treatments were able to reduce the use of these by 52% and 74% of chronic patients were able to stop, reduce or remain off all preventive medications. 59% of all patients were HIT-6 responders, 67% were SF-36 responders.CONCLUSIONS: This open-label registry corroborates that SPG stimulation is an effective therapy for CH patients providing therapeutic benefits and improvements in use of medication as well as headache impact and quality of life.

AB - BACKGROUND: Cluster headache (CH) is a disabling primary headache disorder characterized by severe periorbital pain. A subset of patients does not respond to established pharmacological therapy. This study examines outcomes of a cohort of mainly chronic CH patients treated with sphenopalatine ganglion (SPG) stimulation.METHODS: Patients were followed in an open-label prospective study for 12 months. Ninety-seven CH patients (88 chronic, 9 episodic) underwent trans-oral insertion of a microstimulator targeting the SPG. Patients recorded stimulation effect prospectively for individual attacks. Frequency, use of preventive and acute medications, headache impact (HIT-6) and quality of life measures (SF-36v2) were monitored at clinic visits. Per protocol, frequency responders experienced ≥ 50% reduction in attack frequency and acute responders treated ≥ 50% of attacks. HIT-6 responders experienced an improvement ≥ 2.3 units and SF-36 responders ≥ 4 units vs. baseline.RESULTS: Eighty-five patients (78 chronic, 7 episodic) remained implanted and were evaluated for effectiveness at 12 months. In total, 68% of all patients were responders, 55% of chronic patients were frequency responders and 32% of all patients were acute responders. 67% of patients using acute treatments were able to reduce the use of these by 52% and 74% of chronic patients were able to stop, reduce or remain off all preventive medications. 59% of all patients were HIT-6 responders, 67% were SF-36 responders.CONCLUSIONS: This open-label registry corroborates that SPG stimulation is an effective therapy for CH patients providing therapeutic benefits and improvements in use of medication as well as headache impact and quality of life.

KW - Adult

KW - Aged

KW - Cluster Headache/therapy

KW - Electric Stimulation Therapy/instrumentation

KW - Europe

KW - Female

KW - Ganglia, Parasympathetic

KW - Humans

KW - Male

KW - Middle Aged

KW - Outcome Assessment (Health Care)

KW - Prospective Studies

KW - Registries

KW - Young Adult

U2 - 10.1186/s10194-017-0828-9

DO - 10.1186/s10194-017-0828-9

M3 - Journal article

C2 - 29349561

SN - 1129-2369

VL - 19

JO - The Journal of Headache and Pain

JF - The Journal of Headache and Pain

M1 - 6

ER -

Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater